首页 › 基金 › Opaleye Management Inc. › CBIO
Opaleye Management Inc. 对 CBIO 的持仓历史
CRESCENT BIOPHARMA INC. · 医疗保健
Opaleye Management Inc. 在 Q2 2026 的 13F 申报中披露持有 CBIO(CRESCENT BIOPHARMA INC.)1,319,351 股,市值约 US$23.7M,约占其申报组合的 2.15%,在其申报持仓中市值排名第 12 位。 Opaleye Management Inc. 最近 3 个申报季度中有 3 个季度披露了 CBIO 持仓,最早可追溯至 Q4 2025。
最后更新: 2026-10-24 · 来源: SEC EDGAR Form 13F-HR
Opaleye Management Inc. 对 CBIO 的持仓演变
Opaleye Management Inc. 于 Q4 2025 首次披露 CBIO 持仓:1,178,300 股(约 US$14.0M)。 该持仓在 Q1 2026 达到峰值 1,312,615 股,市值约 US$24.1M。 在 3 次申报中,Opaleye Management Inc. 2 次增持、0 次减持、0 次保持不变。 最近一期申报(Q2 2026)显示持股 1,319,351 股、市值约 US$23.7M,环比增持 6,736 股。。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q4 2025 | 1.18M | $13.97M | 新进 |
| Q1 2026 | 1.31M | $24.11M | 增持 |
| Q2 2026 | 1.32M | $23.75M | 增持 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 CBIO 与 13F 数据
CBIO(CRESCENT BIOPHARMA INC.)属于医疗保健行业。我们追踪的基金中还有 71 只申报持有 CBIO,申报仓位最大的包括:BVF INC/IL (US$49.5M), Fairmount Funds Management LLC (US$49.5M), Venrock Adviser, LLC (US$38.4M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 CBIO 的基金
- BVF INC/IL 2.75M 股 · $49.48M · Q2 2026
- Fairmount Funds Management LLC 2.75M 股 · $49.46M · Q2 2026
- Venrock Adviser, LLC 2.13M 股 · $38.40M · Q2 2026
- Logos Global Management LP 1.90M 股 · $34.20M · Q2 2026
- FCPM III SERVICES B.V. 1.68M 股 · $30.20M · Q2 2026
- Vestal Point Capital, LP 1.63M 股 · $29.34M · Q2 2026
- TANG CAPITAL MANAGEMENT LLC 1.16M 股 · $20.88M · Q2 2026
- Boxer Capital Management, LLC 453.69K 股 · $8.17M · Q2 2026
- NEXTBio Capital Management LP 372.86K 股 · $6.71M · Q2 2026
- Remedium Capital Partners, LLC 361.25K 股 · $6.50M · Q2 2026
- STEMPOINT CAPITAL LP 182.38K 股 · $3.28M · Q2 2026
- Exome Asset Management LLC 127.77K 股 · $2.30M · Q2 2026
更多关于 Opaleye Management Inc.
常见问题
How long has Opaleye Management Inc. held CBIO?
Opaleye Management Inc. has disclosed CBIO holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
What is Opaleye Management Inc.'s current position in CBIO?
As of Q2 2026, Opaleye Management Inc. holds 1.32M shares of CBIO (CRESCENT BIOPHARMA INC.), valued at $23.75M, representing 2.15% of its reported portfolio and ranking #12.
Has Opaleye Management Inc. been buying or selling CBIO?
In the latest 13F filing (Q2 2026), Opaleye Management Inc. increased its position in CBIO. The position peaked in Q1 2026 at 1.31M shares.
Which other funds hold CBIO?
Other major institutional holders of CBIO include BVF INC/IL, Fairmount Funds Management LLC, Venrock Adviser, LLC, among 71 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.